| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.88 [0.78, 0.99] | | < 1 | | 60% | 8 studies (8/-) | 98.4 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.62 [0.51, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.60 [0.48, 0.74] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 1.13 [0.85, 1.49] | | < 1 | | 94% | 8 studies (8/-) | 19.6 % | some concern | not evaluable | moderate | important | - |
| DCR | 0.77 [0.31, 1.90] | | > 1 | | 92% | 3 studies (3/-) | 28.6 % | some concern | not evaluable | moderate | non important | - |
| irORR | 0.24 [0.03, 2.19] | | > 1 | | 0% | 1 study (1/-) | 10.3 % | NA | not evaluable | | non important | - |
| irPFS | 1.44 [1.09, 1.91] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.98 [0.54, 1.76] | | > 1 | | 90% | 7 studies (7/-) | 47.2 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.01 [0.51, 2.00] | | < 1 | | 63% | 4 studies (4/-) | 49.2 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.58 [0.18, 1.81] | | < 1 | | 97% | 4 studies (4/-) | 82.6 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 0.86 [0.57, 1.30] | | < 1 | | 0% | 4 studies (4/-) | 75.8 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.61 [0.24, 1.56] | | < 1 | | 92% | 4 studies (4/-) | 85.0 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.69 [0.29, 1.66] | | < 1 | | 0% | 1 study (1/-) | 79.5 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.97 [0.59, 1.60] | | < 1 | | 71% | 2 studies (2/-) | 54.1 % | some concern | not evaluable | moderate | non important | - |
| SAE (grade 3-4) | 0.92 [0.61, 1.40] | | < 1 | | 0% | 1 study (1/-) | 64.6 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.52 [0.84, 2.76] | | < 1 | | 71% | 3 studies (3/-) | 8.5 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 1.85 [1.39, 2.48] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.67 [0.30, 1.51] | | < 1 | | 96% | 8 studies (8/-) | 83.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.77 [0.30, 2.00] | | < 1 | | 96% | 6 studies (6/-) | 70.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.72 [0.76, 3.90] | | < 1 | | 0% | 6 studies (6/-) | 9.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.77 [0.31, 1.89] | | < 1 | | 89% | 6 studies (6/-) | 71.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.49 [0.51, 4.32] | | < 1 | | 56% | 2 studies (2/-) | 23.4 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.50 [0.08, 3.03] | | < 1 | | 0% | 4 studies (4/-) | 77.5 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.46 [0.15, 1.40] | | < 1 | | 89% | 5 studies (5/-) | 91.4 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.54 [0.25, 1.15] | | < 1 | | 24% | 5 studies (5/-) | 94.5 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.73 [0.09, 6.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.90 [0.12, 6.89] | | < 1 | | 21% | 3 studies (3/-) | 54.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.64 [0.30, 1.35] | | < 1 | | 41% | 7 studies (7/-) | 87.9 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.77 [0.35, 1.73] | | < 1 | | 56% | 7 studies (7/-) | 73.4 % | some concern | not evaluable | moderate | non important | - |
| Dizziness TRAE (grade 3-4) | 0.73 [0.09, 6.31] | | < 1 | | 0% | 2 studies (2/-) | 61.0 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 4.01 [0.37, 43.00] | | < 1 | | 2% | 2 studies (2/-) | 12.7 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.78 [0.37, 1.63] | | < 1 | | 59% | 7 studies (7/-) | 74.5 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.40] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.73 [1.04, 2.86] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 7.60 [0.40, 144.43] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.81 [0.97, 3.36] | | < 1 | | 0% | 1 study (1/-) | 3.0 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.68 [0.04, 10.84] | | < 1 | | 0% | 2 studies (2/-) | 60.8 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 4.88 [1.25, 19.13] | | < 1 | | 7% | 5 studies (5/-) | 1.2 % | some concern | serious | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.95 [0.85, 4.47] | | < 1 | | 0% | 3 studies (3/-) | 5.8 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.97 [0.40, 2.40] | | < 1 | | 0% | 3 studies (3/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.74 [0.36, 8.39] | | < 1 | | 50% | 2 studies (2/-) | 24.5 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.95 [0.09, 10.52] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 2.43 [0.23, 25.98] | | < 1 | | 34% | 2 studies (2/-) | 23.2 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.20 [0.01, 4.07] | | < 1 | | 77% | 2 studies (2/-) | 85.1 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 0.79 [0.02, 40.48] | | < 1 | | 0% | 1 study (1/-) | 54.6 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.65 [0.32, 1.32] | | < 1 | | 35% | 7 studies (7/-) | 88.2 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.25 [0.08, 0.74] | | < 1 | | 88% | 5 studies (5/-) | 99.4 % | some concern | serious | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.87 [0.28, 2.71] | | < 1 | | 54% | 4 studies (4/-) | 59.8 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.47 [0.02, 14.02] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.28 [0.74, 2.22] | | < 1 | | 2% | 5 studies (5/-) | 19.0 % | some concern | not evaluable | moderate | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 1.33 [0.50, 3.53] | | < 1 | | 10% | 2 studies (2/-) | 28.5 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.04 [0.21, 20.20] | | < 1 | | 0% | 2 studies (2/-) | 27.2 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.77 [0.11, 5.52] | | < 1 | | 0% | 4 studies (4/-) | 60.0 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.98 [0.15, 6.45] | | < 1 | | 0% | 4 studies (4/-) | 51.0 % | low | not evaluable | high | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 5.92 [0.71, 49.31] | | < 1 | | 0% | 1 study (1/-) | 5.1 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 13.96 [1.83, 106.45] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.88 [0.06, 56.28] | | < 1 | | 0% | 1 study (1/-) | 36.0 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 4.36 [1.79, 10.66] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.34 [0.02, 6.97] | | < 1 | | 77% | 2 studies (2/-) | 75.7 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.00 [0.38, 2.62] | | < 1 | | 46% | 3 studies (3/-) | 50.3 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.61 [0.32, 1.17] | | < 1 | | 22% | 5 studies (5/-) | 93.2 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.44 [0.06, 3.49] | | < 1 | | 36% | 3 studies (3/-) | 77.9 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 1.14 [0.43, 3.04] | | < 1 | | 0% | 1 study (1/-) | 39.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.97 [0.54, 1.75] | | < 1 | | 0% | 1 study (1/-) | 53.7 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 2.48 [0.54, 11.47] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.73 [0.12, 4.41] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.54 [0.20, 1.42] | | < 1 | | 0% | 1 study (1/-) | 89.5 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.96 [0.22, 17.71] | | < 1 | | 0% | 1 study (1/-) | 27.5 % | NA | not evaluable | | non important | - |
| Dyspepsia AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.96 [0.09, 43.66] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.29 [0.07, 1.21] | | < 1 | | 0% | 1 study (1/-) | 95.5 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 1.48 [0.47, 4.67] | | < 1 | | 0% | 1 study (1/-) | 25.2 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 1.31 [0.34, 5.00] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.24 [0.02, 2.68] | | < 1 | | 0% | 1 study (1/-) | 87.4 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.47 [0.15, 14.22] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.65 [0.14, 2.92] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
